Company profile for Abbott Laboratories

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We understand that the first step to living your best life is good health. Everything we make is designed to help you do just that. That’s our commitment to building life-changing technologies that keep your heart healthy, nourish your body at every stage of life, help you feel and move better, and bring you information, medicines and breakthroughs to manage your health.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
100 Abbott Park Road, Abbott Park, IL 60064 - (224) 667-6100
Telephone
Telephone
+91-22-3816 2000
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

CPhI North America

Not Confirmed

envelop Contact Supplier

CPhI North America

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

INTERVIEW #SpeakPharma

[Sponsored by another company]
“Our unmatched efficiency and track record of faster DMF filings give our customers a critical competitive advantage”
This week, SpeakPharma interviews Pete Werth III, the new president of ChemWerth, a company that has been at the forefront of the generic pharmaceutical industry for over four decades. He shares his vision for ChemWerth, which includes his commitment to strengthening global manufacturing relationships, and enhancing supply chain resilience. Additionally, he highlights the key aspects of a successful drug master file (DMF). HIGHLIGHTS// Pete Werth III, the new president of ChemWerth/ vision for ChemWerth/ commitment to strengthening global manufacturing relationships/ key aspects of a successful drug master file Your father, Peter J. Werth, is recognized as one of the founders of the generic pharmaceutical industry, having built ChemWerth from the ground up over four decades ago. How do you view his legacy? As you take the helm, what key lessons or principles from his leadership do you intend to carry forward? My father, Peter J. Werth, is a true pioneer in the generic pharmaceutical industry. Over his 42‐year tenure, he not only built ChemWerth from a humble garage startup into a global leader in generic API development but also established standards that many in our industry now take for granted. Under his leadership, we filed our very first DMF in 1987 and have since achieved more than 500 DMF filings. With an average review cycle of just 0.79, we have been far outperforming the industry average of 2.5 cycles. His focus on quality, regulatory excellence, and a relentless commitment to customers’ success set the foundation for our reputation as a trusted supplier of over 500 APIs sourced from more than 30 cGMP-certified facilities worldwide. Equally inspiring is his dedication to nurture long-term, mutually beneficial relationships with manufacturing partners across the US, Europe, India, and China, as well as his passion for giving back to the community through philanthropic initiatives. As I take the helm, I intend to build on his guiding principles — sustaining our high standards of quality and compliance while pursuing innovation in regulatory strategy, diversifying our supply chain, and embracing new technologies and approaches to remain competitive in an evolving market. I will also strive to continue his legacy of mentorship, ensuring that our company culture remains rooted in integrity and diligence, with an unyielding focus on making safe, affordable medicines available worldwide. HIGHLIGHTS// trusted supplier of over 500 APIs/ 30 cGMP-certified facilities worldwide/ embracing new technologies and approaches to remain competitive What are your top priorities as the new president of ChemWerth? How do you plan to strengthen and expand relationships with manufacturers worldwide? My immediate priorities as the new president are twofold: to enhance the value we deliver to our customers and, to deepen our relationships with our manufacturing partners worldwide. We will further diversify our supply chain and broaden our product portfolio. Our expansion plans include upgrading equipment, and hiring additional highly skilled scientists, engineers, and GMP auditors. We will also leverage our proprietary product selection and regulatory submission processes. These processes help us get the regulatory filing right the first time, and allows us to be approved 44 percent faster than the industry average. This helps our customers gain a competitive edge in the market. In essence, by strengthening operational excellence and expanding our global network, we intend to continue the company’s long-standing commitment to customer success and process innovation. We plan to reinforce our long-standing relationships with our manufacturers — especially those in strategic markets like China and India — by helping our partners meet the highest standards of regulatory compliance and current good manufacturing practice (cGMP) quality. This balanced approach of strengthening existing partnerships while pioneering new ones is key to maintaining and growing our competitive edge. HIGHLIGHTS// diversify our supply chain and broaden our product portfolio/ commitment to customer success and process innovation/ filings approved 44 percent faster than the industry average When ChemWerth last spoke to PharmaCompass, there was a mention of investing millions of dollars in expanding manufacturing partnerships in China and India. Can you elaborate on the success of these partnerships, and how have they contributed to ChemWerth’s overall growth? Our strategic, multimillion-dollar investments in manufacturing partnerships are a cornerstone of our growth strategy. Over the past few years, these joint ventures have proven their worth by diversifying our supply base and mitigating the risk of global supply chain disruptions — a lesson that became all too clear during the Covid-19 pandemic. These investments are already paying dividends. They help us support manufacturers producing steroids, hormones, veterinary products, and large-volume APIs, while also accelerating the development of small-molecule inhibitors and new generic APIs. We have ensured that our partners are equipped with the latest equipment and trained personnel to meet cGMP standards. By partnering with facilities in these markets, we now have access to state-of-the-art production capabilities that enable us to produce a wider range of APIs at competitive costs. The success of these partnerships is evident in our ability to consistently file DMFs rapidly — often on the first cycle — and deliver affordable, high-quality medicines to patients worldwide. This supports our clients’ growth trajectory and has helped us expand into new markets. This strategy has reinforced our global footprint — supporting our presence in 38 countries with over 100 products — and positioned us well to capitalize on a global generic drug market projected to grow at a compounded annual growth rate of 5.4 percent from 2022 to 2030, to reach a size of US$ 671 billion by 2030. HIGHLIGHTS// strategic multimillion-dollar investments/ support manufacturers producing steroid, hormone, veterinary products/ development of small-molecule inhibitors and new generic APIs/ ensured partners are equipped with the latest equipment and trained personnel ChemWerth has an impressive track record, and an over 40-year relationship with the US Food and Drug Administration (FDA). What are the key aspects of a successful DMF? Are there specific challenges manufacturers face in preparing DMFs, and how does ChemWerth help them overcome these hurdles? ChemWerth’s record of filing over 500 DMFs in 38 countries reflects our commitment to excellence in regulatory compliance and quality management. A successful DMF is built on comprehensive documentation that rigorously follows cGMP guidelines, robust analytical validation, and detailed tracking of every step. Every DMF we file meticulously details the entire manufacturing process — from raw material acquisition to final batch production. This comprehensive approach ensures that our submissions meet the rigorous quality, safety, and efficacy standards expected by the FDA. Our team stays continuously updated on the evolving guidelines and protocols, which allows us to file DMFs that align with current FDA practices. We recognize that many manufacturers face challenges such as complex regulatory requirements, lengthy review cycles, and the need for precise coordination between various production stages. ChemWerth helps them overcome these hurdles by offering end-to-end regulatory support, detailed internal audits, and continuous training on cGMP and FDA requirements. Our efficiency is a critical competitive advantage. By receiving approvals 44 percent faster than the industry average, we help our customers get their products to market faster, resulting in larger market share and increased profits. HIGHLIGHTS// over 500 DMFs in 38 countries/ robust analytical validation/ end-to-end regulatory support What is your vision for ChemWerth over the next few years? How do you plan to navigate the challenges and opportunities in the generic pharmaceutical industry? I plan to continue to add value for our customers, and look for innovative ways to compete in today’s generic pharmaceutical landscape. At ChemWerth, our vision for the future is rooted in both our proud legacy and our relentless drive for innovation. We will further diversify our supply chain and expand our product portfolio. We have begun leveraging our expertise to supply APIs for biosimilars and new drug applications (NDAs), while maintaining our reputation for rapid regulatory approvals. With unwavering determination, we uphold our “First to Quality. Fast to Market.” approach — delivering high-quality APIs to customers worldwide while leveraging our expertise to give them a competitive edge in their markets. HIGHLIGHTS// supply APIs for biosimilars and NDAs/ give customers a competitive edge in their markets 

Impressions: 923

https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage

Radio Compass
12 Mar 2025

VLOG #PharmaReel

[Sponsored by another company]

DATA COMPILATION #PharmaFlow

[Sponsored by another company]
How Trump’s tariffs on imported drugs can hurt supply chains, consumers and industry
Ever since Donald Trump has moved into the White House for a second term, there has been turmoil across the world. One of the issues that has been of concern is ‘tariffs’. Trump is keen to reduce United States’ trade deficit through import tariffs.Since the mid-1990s, the US has been importing drugs from across the world largely tariff-free, and its drug imports have risen consistently. In 2024, the US imported US$ 213 billion worth of medicines, which was more than two and a half times the total of its drug imports ten years back.Until recently, it seemed like the administration would spare the pharmaceutical sector. But at a fundraiser dinner held for the Republican Party last week, Trump said: “We're going to be announcing very shortly a major tariff on pharmaceuticals”. The pharma tariffs, he said, would be “at a level that you haven’t really seen before”.The US is the largest consumer of pharmaceuticals globally, accounting for 45 percent of global sales. Given the nature of the global pharma industry, ‘major tariffs’ would have far-reaching impact. PharmaCompass studies the likely impact of tariffs on drug imports into the US, and whether they would serve the purpose they intend to.Cost of import tariffs, setting up domestic capacities will be borne by US consumersThe Trump administration has two key objectives behind implementing drug import tariffs. One, it wants to secure US drug supply chains by onshoring drug production. Two, it wants to create more manufacturing jobs in the US. Will tariffs be successful in achieving these objectives?Importers generally pay the tax and pass it on to the consumer. Bernstein analyst Courtney Breen estimates that in the worst-case scenario, tariffs could result in an extra US$ 53 billion in costs paid for pharmaceutical imports. According to economist Ernie Tedeschi, “costs for prescription drugs would rise by an average of around US$ 600 per year per household” in the US. Not all of that would be ‘out-of-pocket’, and families may “end up paying higher insurance premiums [and] higher co-pays”.Many drugmakers may want to avoid that cost, and shift manufacturing to the US. Though American drugmakers Eli Lilly and Johnson & Johnson have announced mega investments in the US, it’s difficult to say if other drugmakers will find it viable to set up capacities. Having said that, just this week Novartis announced a US$ 23 billion investment in the US.Overall, resources are expensive in the US. Due to heavy reliance on imports, the country does not have industrial plants needed for large-scale production. Factors like labor regulations, high cost of living, mandatory benefits etc, have made the workforce quite expensive. It’s puzzling how any drugmaker will overcome these challenges and create manufacturing jobs. Even if they do, the high costs of manufacturing will translate into costlier drugs.According to a recent report undertaken by RAND, prescription drug prices in the US are on an average 2.78 times those seen in 33 other nations. With tariffs, that gap will widen further.Drug supply chains are complex; moving capacities to US costly, time-consumingAccording to the US Food and Drug Administration (FDA), as of August 2019, only 28 percent of the facilities producing APIs for the US market were located domestically. The remaining 72 percent were overseas, with nearly half of its generics coming from India.The US is also highly dependent on drug imports for critical therapies. In 2024, the European Union supplied US$ 127 billion worth of high-value branded medicines to the US.The pharmaceutical supply chain is complex. There are a series of chemical steps involved in making any drug, with each step often being performed in different locations.The supply chain is determined by a variety of factors, such as availability of cheap labour, tax rates, supply of raw materials etc. For instance, Ireland has a very low corporate tax rate. Therefore, it has emerged as a hub for the production of APIs used in blockbuster medicines, such as Lilly’s Zepbound and Merck’s Keytruda.Moving production to the US will take five to seven years per plant. Each plant will cost US$ 2 billion or more. And it will have to go through several checks to meet America’s high regulatory standards. It is a long, arduous and unnecessary exercise, when capacities, expertise and cheaper labor is already existing in other countries.Europe also plans to onshore, leading to turbulent shift in trade dynamicsLike the US, Europe too is heavily reliant on China and India, and is working towards reducing its dependence. Over the years, Europe has moved significant resources into the US, especially in R&D. American drugmakers like Pfizer and Johnson & Johnson, on the other hand, manufacture many of their drugs in Europe and export them back to the US. Tariffs, therefore, will impact European exports in a big way. Drugmakers confronted European Commission President Ursula von der Leyen soon after Trump spoke about the pharma tariffs. These drugmakers, led by Novo Nordisk’s CEO Lars Fruergaard Jørgensen, asked for a “rapid, radical policy change” so that R&D and manufacturing doesn’t get directed towards the US.According to these drugmakers, up to 85 per cent of capital investments (about €50.6 billion, or US$ 56 billion) and up to 50 per cent of R&D expenditures (about €52.6 billion or US$ 58 billion) are potentially at risk. These figures are taken from a total of €164.8 billion (US$ 182 billion) worth of pharmaceutical investment planned in the EU during 2025 to 2029.Tariffs will test low margins of generics, may put a pause on dealmakingTariffs will have a different impact on generics. According to a Brookings report, while tariffs will “provide a strong incentive for increasing US manufacturing of brand-name drugs”, it will not be incentive enough for older, off-patent generic drugs, which “represent over 90 percent of the volume but only a small share of spending”.It will be difficult for generic drugmakers to onshore due to high capital expenditures and low and uncertain returns on investment. In fact, tariff pressure will test the wafer-thin margins of generic drugmakers in both the US and overseas. This could lead to product discontinuations or drastic cost cutting, which in turn could erode product quality.In the end, as  Arthur Wong, senior director of corporate ratings, healthcare, at S&P Global Ratings, puts it, all this chaos is going to “put a pause [on] or distract” from another key pharma function: dealmaking. The time for executing M&As was now. But we can’t expect dealmaking to return until the second half of 2025. 

Impressions: 1598

https://www.pharmacompass.com/radio-compass-blog/how-trump-s-tariffs-on-imported-drugs-can-hurt-supply-chains-consumers-and-industry

#Phispers by PHARMACOMPASS
17 Apr 2025

NEWS #PharmaBuzz

read-more
read-more

https://www.indianpharmapost.com/people/abbott-india-elevates-anushree-kunhambu-as-associate-director-new-product-introduction-and-therapy-area-strategy-17036

INDPHARMAPOST
17 Apr 2025

https://www.prnewswire.com/news-releases/abbott-reports-first-quarter-2025-results-and-reaffirms-full-year-guidance-302430212.html

PR NEWSWIRE
16 Apr 2025

https://www.prnewswire.com/news-releases/new-late-breaking-data-reinforce-benefits-of-abbotts-triclip-for-people-with-leaky-tricuspid-heart-valve-302413554.html

PR NEWSWIRE
31 Mar 2025

https://www.prnewswire.com/news-releases/abbott-receives-ce-mark-for-its-volt-pulsed-field-ablation-system-to-treat-patients-with-abnormal-heart-rhythms-302408739.html

PR NEWSWIRE
27 Mar 2025

https://www.prnewswire.com/news-releases/abbott-hosts-conference-call-for-first-quarter-earnings-302408887.html

PR NEWSWIRE
26 Mar 2025

https://www.prnewswire.com/news-releases/abbott-initiates-new-intravascular-lithotripsy-clinical-trial-to-improve-outcomes-in-patients-with-coronary-artery-disease-302408764.html

PR NEWSWIRE
24 Mar 2025

Excipients

Click here to find the perfect excipient manufacturers by their capabilities

Inspections and registrations

Upload your audits for free, ask us

ABOUT THIS PAGE

Contact Abbott Laboratories and get a quotation

Abbott Laboratories is a supplier offers 120 products (APIs, Excipients or Intermediates).

Find a price of Lactulose bulk with DMF, CEP, JDMF offered by Abbott Laboratories

Find a price of Dydrogesterone bulk with CEP, JDMF offered by Abbott Laboratories

Find a price of Verapamil Hydrochloride bulk with DMF, CEP offered by Abbott Laboratories

Find a price of Chondroitin Sulfate Sodium bulk with DMF offered by Abbott Laboratories

Find a price of Clarithromycin bulk with CEP offered by Abbott Laboratories

Find a price of Lactulose bulk with CEP offered by Abbott Laboratories

Find a price of Pancreatin bulk with DMF offered by Abbott Laboratories

Find a price of Thyroid bulk with DMF offered by Abbott Laboratories

Find a price of Trandolapril bulk with CEP offered by Abbott Laboratories

Find a price of Zotarolimus bulk with DMF offered by Abbott Laboratories

Find a price of 2-Thiouracil bulk offered by Abbott Laboratories

Find a price of Amikacin Sulfate bulk offered by Abbott Laboratories

Find a price of Amrinone bulk offered by Abbott Laboratories

Find a price of Atracurium Besylate bulk offered by Abbott Laboratories

Find a price of Betaxolol bulk offered by Abbott Laboratories

Find a price of Bifeprunox bulk offered by Abbott Laboratories

Find a price of Bradykinin bulk offered by Abbott Laboratories

Find a price of Butabarbital bulk offered by Abbott Laboratories

Find a price of Butorphanol Tartrate bulk offered by Abbott Laboratories

Find a price of Carbidopa bulk offered by Abbott Laboratories

Find a price of CAS 50-28-2 bulk offered by Abbott Laboratories

Find a price of Clindamycin Hydrochloride bulk offered by Abbott Laboratories

Find a price of Cytolex bulk offered by Abbott Laboratories

Find a price of Dicumarol bulk offered by Abbott Laboratories

Find a price of Diethylstilbestrol bulk offered by Abbott Laboratories

Find a price of Dimethadione bulk offered by Abbott Laboratories

Find a price of Divalproex Sodium bulk offered by Abbott Laboratories

Find a price of Dobutamine Hydrochloride bulk offered by Abbott Laboratories

Find a price of Enflurane bulk offered by Abbott Laboratories

Find a price of Erythromycin bulk offered by Abbott Laboratories

Find a price of Erythromycin Estolate bulk offered by Abbott Laboratories

Find a price of Erythromycin Ethyl Succinate bulk offered by Abbott Laboratories

Find a price of Erythromycin Stearate bulk offered by Abbott Laboratories

Find a price of Erythromyclamine bulk offered by Abbott Laboratories

Find a price of Ethchlorvynol bulk offered by Abbott Laboratories

Find a price of Fentanyl bulk offered by Abbott Laboratories

Find a price of Fentanyl Citrate bulk offered by Abbott Laboratories

Find a price of Genesa bulk offered by Abbott Laboratories

Find a price of Glipizide bulk offered by Abbott Laboratories

Find a price of Gonadorelin Acetate bulk offered by Abbott Laboratories

Find a price of Haloperidol bulk offered by Abbott Laboratories

Find a price of Hydrochlorothiazide bulk offered by Abbott Laboratories

Find a price of Hydroxychloroquine Sulphate bulk offered by Abbott Laboratories

Find a price of Inositol bulk offered by Abbott Laboratories

Find a price of Iopamidol bulk offered by Abbott Laboratories

Find a price of Ketorolac Trometamol bulk offered by Abbott Laboratories

Find a price of Lincomycin Hydrochloride bulk offered by Abbott Laboratories

Find a price of Lovastatin bulk offered by Abbott Laboratories

Find a price of MAPROTILINE HYDROCHLORIDE bulk offered by Abbott Laboratories

Find a price of Meprobamate bulk offered by Abbott Laboratories

Find a price of Methocarbamol bulk offered by Abbott Laboratories

Find a price of Methyclothiazide bulk offered by Abbott Laboratories

Find a price of Methylprednisolone Hemisuccinate bulk offered by Abbott Laboratories

Find a price of Midazolam bulk offered by Abbott Laboratories

Find a price of Oxtriphylline bulk offered by Abbott Laboratories

Find a price of Oxybutynin Hydrochloride bulk offered by Abbott Laboratories

Find a price of Paracetamol bulk offered by Abbott Laboratories

Find a price of Pentamidine Isethionate bulk offered by Abbott Laboratories

Find a price of Pentetic Acid bulk offered by Abbott Laboratories

Find a price of Pentigide bulk offered by Abbott Laboratories

Find a price of Prazosin Hydrochloride bulk offered by Abbott Laboratories

Find a price of Propofol bulk offered by Abbott Laboratories

Find a price of Propoxyphene Napsylate bulk offered by Abbott Laboratories

Find a price of Selenium Sulfide bulk offered by Abbott Laboratories

Find a price of Simethicone bulk offered by Abbott Laboratories

Find a price of Sirolimus bulk offered by Abbott Laboratories

Find a price of Sodium Arsanilate bulk offered by Abbott Laboratories

Find a price of Spectinomycin bulk offered by Abbott Laboratories

Find a price of Spectinomycin Dihydrochloride Pentahydrate bulk offered by Abbott Laboratories

Find a price of Succinylcholine Chloride bulk offered by Abbott Laboratories

Find a price of Sulfiram bulk offered by Abbott Laboratories

Find a price of Terazosin HCl bulk offered by Abbott Laboratories

Find a price of Tetracycline bulk offered by Abbott Laboratories

Find a price of Thiamylal bulk offered by Abbott Laboratories

Find a price of Thyrotropin-Releasing Hormone bulk offered by Abbott Laboratories

Find a price of Tromethamine API bulk offered by Abbott Laboratories

Find a price of Tubocurarine Chloride bulk offered by Abbott Laboratories

Find a price of Vancomycin Hydrochloride bulk offered by Abbott Laboratories

Find a price of Verapamil bulk offered by Abbott Laboratories

Find a price of Vitamin K1 bulk offered by Abbott Laboratories

Find a price of SEMI-WORKS AREA IN QUEENBOROUGH, KENT, UNITED KINGDOM bulk offered by Abbott Laboratories

Find a price of RENAL KETO ACID PRODUCT bulk offered by Abbott Laboratories

Find a price of FACILITIES LOCATED IN QUEENBOROUGH, KENT, UK bulk offered by Abbott Laboratories

Find a price of 2-(2-FORMYLHYDRAZINO)-4-(5-NITRO-2-FURYL)-THIAZOLE (AS-L7665)&A-2L203 bulk offered by Abbott Laboratories

Find a price of FACILS, PERSONNEL & GEN OPER PROCEDS FOR THE MURINE CO. FACILS. bulk offered by Abbott Laboratories

Find a price of STD CONTROL PROCEDURES,RAW DRUG CODES FOR SVP & LVP PRODUCTS,5-80 5-81 bulk offered by Abbott Laboratories

Find a price of DEXOXYEPHEDRINE HCL bulk offered by Abbott Laboratories

Find a price of METHAPYRILENE HCL bulk offered by Abbott Laboratories

Find a price of STD TEST METHODS FOR TESTING SVP & LVP PRODUCTS(PERIOD 5-1-80 - 5-1-81 bulk offered by Abbott Laboratories

Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN ROCKY MOUNT, NORTH CAROLINA. bulk offered by Abbott Laboratories

Find a price of NIKKOMYCIN Z HYDROCHLORIDE bulk offered by Abbott Laboratories

Find a price of FACILITIES AND OPERATING PROCEDURES IN LATINA, ITALY (LABORATORI ABBOTT S.P.A.) bulk offered by Abbott Laboratories

Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN NORTH CHICAGO, ILLINOIS. bulk offered by Abbott Laboratories

Find a price of IRON-58 STERILE SOLUTION bulk offered by Abbott Laboratories

Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN QUEENBOURGH, KENT, UNITED KINGDOM. bulk offered by Abbott Laboratories

Find a price of M-259 (NSC 51954) bulk offered by Abbott Laboratories

Find a price of QUALITY ASSURANCE OPERATIONS STANDARDS bulk offered by Abbott Laboratories

Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN MCPHERSON, KANSAS. bulk offered by Abbott Laboratories

Find a price of I-125-FIBRINOGEN (HUMAN) SENSOR bulk offered by Abbott Laboratories

Find a price of STD.CONTROL PROCEDURES,RAW DRUG CODES FOR SVP & LVP PRODUCTS(5-80 5-81 bulk offered by Abbott Laboratories

Find a price of MFGR PROCEDS,CTRLS,FACILS & PACKAGING P.RICO PLANT bulk offered by Abbott Laboratories

Find a price of FACILS., PROCEDS., & CONTROLS-AT THE BARCELONETA, PUERTO RICO PLANT bulk offered by Abbott Laboratories

Find a price of MANUF, PACKAGING AND LABELING OF BULK CALCIUM AND SODIUM CYCLAMATE bulk offered by Abbott Laboratories

Find a price of MANUFACTURING SITE,FACILITES,PERSONNEL, AND GENERAL MANUFACTURING PROCEDURES. bulk offered by Abbott Laboratories

Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN ETHRANE IN QUEENBOUROUGH, KENT, ENGLAND. bulk offered by Abbott Laboratories

Find a price of FACILITIES AND OPERATING PROCEDURES IN QUEENBOROUGH, ENGLAND bulk offered by Abbott Laboratories

Find a price of ANTIBIOTIC M-188 (MACROLIDE ANTIBIOTIC OF THE ERYTHROMYCIN GROUP) bulk offered by Abbott Laboratories

Find a price of CURRICULUM VITAE OF ABBOTT'S THERAPEUTIC COMMITTEE bulk offered by Abbott Laboratories

Find a price of SPEC, STANDARD CONTROL PROCEDS & TEXT METHODS FOR INACTIVE INGREDS. bulk offered by Abbott Laboratories

Find a price of LIFE CARE FLEXIBLE CONTAINERS bulk offered by Abbott Laboratories

Find a price of QUALITY ASSURANCE OPERATION STANDARDS bulk offered by Abbott Laboratories

Find a price of STANDARD TEST METHODS FOR TESTING SVP & LVP PRODUCTS (5-1-80 - 5-1-81) bulk offered by Abbott Laboratories

Find a price of ABBOTT LABS QUALITY ASSURANCE OPERATIONS STANDARDS MANUAL PHARM. DIV. bulk offered by Abbott Laboratories

Find a price of FACILITIES bulk offered by Abbott Laboratories

Find a price of CYCLAMATE, SACCHARIN AND CYCLOHEXYLAMINE bulk offered by Abbott Laboratories

Find a price of Difloxacin bulk offered by Abbott Laboratories

Find a price of Erythromycin Thiocyanate bulk offered by Abbott Laboratories

Find a price of Sarafloxacin bulk offered by Abbott Laboratories

Find a price of Sodium Chloride bulk offered by Abbott Laboratories

Find a price of LAIDLOMYCIN bulk offered by Abbott Laboratories

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty